-
Ocrevus®
Ocrevus® is a disease-modifying therapy designed to treat multiple forms of multiple sclerosis (MS), including relapsing multiple sclerosis and primary progressive multiple sclerosis by targeting B cells in the immune system. At Singlepoint Healthcare, our goal is to provide safe, effective Ocrevus® IV therapy in a comfortable and supportive environment.
How Ocrevus® Works
Ocrevus® is a prescription medication specifically approved for the treatment of adults with relapsing forms of MS, including clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease, as well as primary progressive MS. Administered as an intravenous infusion, Ocrevus® works by targeting CD20-positive B cells, a type of immune cell involved in the inflammatory processes that damage the brain and spinal cord in MS.
For many patients, Ocrevus® treatment results in improved long-term neurological stability, preserved mobility, and greater independence in daily life.
Key Details
Important Information
| Category | Details |
|---|---|
| Conditions It Treats | Relapsing Multiple Sclerosis (RMS), Primary Progressive Multiple Sclerosis (PPMS) |
| Manufacturer | Genentech |
| Administered by | Infusion |
| Frequency | Initial: Two infusions given two weeks apart, Maintenance: One infusion every six months |
| Length of Infusion | 2-4 hours |
| FDA Approval(s) | Relapsing Forms of MS: Approved March 28, 2017 Primary Progressive MS: Approved March 28, 2017 |